Advances in medical sciences · 2025
Prevalence of hepatitis D virus in chronic hepatitis B patients: findings from Poland.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zarębska-Michaluk Dorota, Brzdęk Michał, Dobrowolska Krystyna, Martonik Diana, Parfieniuk-Kowerda Anna, Janczura Jakub, Brzdęk Kinga, Pleśniak Robert, Piszcz Agnes, Flisiak Robert
Аннотация
PURPOSE: This study aimed to determine the prevalence of hepatitis B/hepatitis D virus (HBV/HDV) co-infections in eastern Poland.
MATERIALS/METHODS: We included consecutive patients with chronic hepatitis B treated with nucleos(t)ide analogues (NA) in the study, in whom we performed anti-HDV assays verified by molecular testing.
RESULTS: The analysed population consisted of 398 patients, predominantly male with a median age of 50 years, 58.3 % of whom had comorbidities. Forty-three patients (10.8 %) were diagnosed with cirrhosis. Patients were treated with entecavir, tenofovir, or lamivudine for a median of 5 years. At the start of treatment, the median viral load was 5110 IU/ml, and 98 % of patients achieved viral eradication during the therapy. In the study population, anti-HDV antibodies were detected in 6 patients (1.5 %), 3 men and 3 women, of whom in 1 (0.25 %) the presence of genetic material of the HDV was confirmed by molecular testing. Among anti-HDV-positive patients, 3 (50 %) had cirrhosis, 1 of them underwent liver transplantation, and 2 had extrahepatic malignancy. All of them were negative for hepatitis B virus envelope (HBe) antigen and had antibodies to HBe antigen present at the beginning of antiviral treatment. All anti-HDV-positive patients achieved viral clearance during the therapy.
CONCLUSION: In a population of almost four hundred patients infected with HBV, we observed a low prevalence of anti-HDV antibodies of 1.5 % and HDV replication of only 0.25 %. Half of the 6 patients with serologic evidence of co-infection had cirrhosis, so HDV likely played a role in disease progression.
MATERIALS/METHODS: We included consecutive patients with chronic hepatitis B treated with nucleos(t)ide analogues (NA) in the study, in whom we performed anti-HDV assays verified by molecular testing.
RESULTS: The analysed population consisted of 398 patients, predominantly male with a median age of 50 years, 58.3 % of whom had comorbidities. Forty-three patients (10.8 %) were diagnosed with cirrhosis. Patients were treated with entecavir, tenofovir, or lamivudine for a median of 5 years. At the start of treatment, the median viral load was 5110 IU/ml, and 98 % of patients achieved viral eradication during the therapy. In the study population, anti-HDV antibodies were detected in 6 patients (1.5 %), 3 men and 3 women, of whom in 1 (0.25 %) the presence of genetic material of the HDV was confirmed by molecular testing. Among anti-HDV-positive patients, 3 (50 %) had cirrhosis, 1 of them underwent liver transplantation, and 2 had extrahepatic malignancy. All of them were negative for hepatitis B virus envelope (HBe) antigen and had antibodies to HBe antigen present at the beginning of antiviral treatment. All anti-HDV-positive patients achieved viral clearance during the therapy.
CONCLUSION: In a population of almost four hundred patients infected with HBV, we observed a low prevalence of anti-HDV antibodies of 1.5 % and HDV replication of only 0.25 %. Half of the 6 patients with serologic evidence of co-infection had cirrhosis, so HDV likely played a role in disease progression.